Ann: Information For Retail Shareholders, page-195

Some MSB investors have lost the plot a bit, maddened by their losses no doubt. There is a comment above that the offer price is too low! It got 10 upvotes.

Its hilarious. Is the world going mad, people want to pay a higher spot price for financial assets offering forward returns? But if its offer lower its a bad thing? Anyone going to explain how forward returns to lower starting prices work?

There were quite a few people confusingly buying stock ahead of the record date unaware it was already ex-entitlement it seems from comments too. Probably exaggerated the predictable fall today.

We have one of our resident bullies (or is he shorting one wonders?) going on about SI not taking up his full entitlement, yet failing to point out just how much money his full entitlement would require and that SI hasn't taken up an entitlement for a while - like most ASX CEO's why would he when he will award himself free shares every year and idiot shareholders, in every stock, not just MSB, approve them every AGM?

That SI is taking up some a good sign. MSB by far my worse investment in a wide portfolio, in years of this game, but I intend to take up my entitlement and buy more on the secondary market if it remains <$0.30.

I have no illusions on the poor performance of SI. Sure the FDA very questionable, but SI and co. have similar question marks against their performance. But on weight of the recent range of developments, you'd have to suspect they are getting over the line third time lucky - or rather far better positioned. Whilst we can all throw stones at the FDA (and my favourite the DMSB in the NIH COVID trial) Silviu and co. are managing the trials, ultimately signing off on the endpoints, talking to the FDA and the commercialisation pathways. They can't predict every surprise move by the FDA, but they are best positioned to predict them and have evidently and irrefutably not done a satisfactory job or we would not be zero for four and trading <$0.30.